Using mouse and cell culture models, a study found that gallbladder tumors or cancer cells harboring ERBB2/ERBB3 mutations showed an enhanced effect of anti-PD-1 treatment compared to WT43. The gene discussed is ERBB2; the disease is gallbladder neoplasm.